Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- hepatocellular carcinoma
- Source Database
- CIViC Evidence
- Description
- Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1642
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Hepatocellular Carcinoma
- Evidence Direction
- Supports
- Drug
- Refametinib,Sorafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25294897
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Refametinib | Sensitivity | true |
| Sorafenib | Sensitivity | true |